secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031301
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara Q2 revenue up 28% to record $20.2M; net loss widens to $3.5M
-------------------------------------------------------------------

- Revenue $20.2M, +28% YoY; eleventh consecutive record revenue quarter.
- Net loss $3.5M vs $1.9M; Adjusted EBITDA $0.6M vs ($0.3M).
- Secured $55M non-dilutive term loan from CRG; $15M drawn, up to $39.8M additional.
- New GPO agreement adds over 1,000 contracted facilities; 300+ distributors, +70 since Jan.
- Appointed Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development & Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315224031301/0001493152-24-031301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315224031301/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer